Alizapride: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Indonesia prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Nausea and vomiting

Adult: 75-300 mg/day in divided doses.
Child: 5 mg/kg/day.

Parenteral
Nausea and vomiting associated with cancer chemotherapy

Adult: 2-5 mg/kg/day given by IV/IM in 2 divided doses. 1st dose to be administered 30 min before and the next dose 4-8 hr after admin of cytotoxic drug. For highly emetogenic regimens requiring doses >5 mg/kg, dose may be given via IV infusion over 15 min every 2 hr for 5 doses. Start infusion 30 min before admin of cytotoxic drug. Max: 4.5 g/course of chemotherapy.

Contraindications

Pheochromocytoma, Parkinson's disease, conditions where activation of GI motility is contraindicated (e.g. GI perforation or sub-occlusion).

Special Precautions

Caution in renal impairment. May impair ability to drive or operate machinery.

Adverse Reactions

Drowsiness, dizziness, headache, diarrhoea, extrapyramidal symptoms, amenorrhoea, galactorrhoea.

Food Interaction

Avoid alcohol.

Action

Description:
Mechanism of Action: Alizapride is a methoxybenzamide that is structurally related to metoclopramide. It is a dopamine antagonist with and antiemetic property.
Pharmacokinetics:
Absorption: Well absorbed after oral admin.
Excretion: Excreted mainly unchanged in urine. Elimination half-life: about 3 hr.

MIMS Class

Antiemetics

Disclaimer: This information is independently developed by MIMS based on Alizapride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com